Tag Archives: peripheral vascular disease

ELUVIA: DES en territorio femoropoplíteo con lesiones complejas

ELUVIA: DES in Complex Femoropopliteal Lesions

ELUVIA: DES in Complex Femoropopliteal Lesions

Paclitaxel-eluting stent Eluvia showed promising results after two years with a revascularization freedom rate of 80% despite the fact that these were complex femoropopliteal lesions. As the safety of paclitaxel-eluting devices becomes more consistent, more studies on its efficacy are being published. Back in 2018, the safety of paclitaxel-eluting balloons and stents was under scrutiny

ACC 2021 | VOYAGER PAD: utilidad del rivaroxaban luego de una angioplastia periférica

ACC 2021 | VOYAGER PAD: Usefulness of Rivaroxaban After Peripheral Angioplasty

Patients with peripheral vascular disease who undergo angioplasty in the lower limbs find benefit from treatment with rivaroxaban, according to the VOYAGER PAD study, presented at the scientific sessions of the American College of Cardiology (ACC) 2021 Congress and simultaneously published in JACC. Patients with said disease present a higher risk of ischemic events not

SAFE-PAD: Dispositivos liberadores de paclitaxel en enfermedad periférica

ACC 2021 | SAFE-PAD: Paclitaxel-Eluting Devices in Peripheral Disease

This work was conducted alongside the US Food and Drug Administration (FDA) to investigate the association between all-cause mortality and paclitaxel-eluting devices in peripheral vascular disease. According to data from SAFE-PAD, presented at the American College of Cardiology (ACC) 2021 Congress and simultaneously published in JAMA, there is no increase in mortality compared with conventional

Webinar SOLACI Research | Angioplastia de miembros inferiores. Registro LATAM Periférico

12/05 | SOLACI Research Webinar: Lower Limb Angioplasty. LATAM Peripheral Registry

Do not miss the next SOLACI Research event, where we will be presenting LATAM Peripheral Research Registry! This registry is meant to collect data and clinical information about peripheral vascular disease across Latin America to determine the best evidence-based therapies.  This is why we are carrying out a live virtual event you cannot miss, where

Diabetes y enfermedad vascular periférica: viejas drogas con nueva evidencia

Diabetes and Peripheral Vascular Disease: Old Drugs, New Evidence

This paper, recently published in JAHA, showed that patients with type 2 diabetes mellitus exhibiting lower-limb vascular disease benefit from combining cilostazol and clopidogrel. Treatment for at least 6 months with clopidogrel (75 mg/QD) plus cilostazol (100 mg/BID) significantly reduces ischemic events—including stroke, infarction, and death from vascular causes—compared with clopidogrel monotherapy. Adding cilostazol reduces ischemic events, but that

Aortic Aneurysms Treated with Endologix AFX Require Special Followup

An FDA document recently published reminds doctors and patients of the need of annual follow up of abdominal aortic aneurysm patients receiving Endologix AFX endoprostheses, with imaging, and for life.  The reason behind this recommendation is the risk of type III leaks.  In 2019, the FDA had alerted us against this issue after finding a

Continuar con la actividad física luego de un IAM reduce la mortalidad

The Key We Are Overlooking in Peripheral Vascular Disease

To change the prognosis of peripheral vascular disease patients, a referral for supervised exercise is paramount. This should be a cultural change, not only an individual recommendation. A physically active lifestyle reduces the risk of cardiovascular events and functional impairment in patients with peripheral vascular disease. The novelty of this work (forthcoming in Eur J

angioplastia femoral

SOLACI PERIPHERAL | 4th Clinical Case: Thoracic Aortic Dissection in Patient with Complex Arch

A new clinical case to keep learning with colleagues! Today, we present a Thoracic Aortic Dissection in Patient with Complex Arch. This is the 4th case for SOLACI Peripheral, which continues its mission: to deepen knowledge exchange among Latin American interventional cardiologists. Tell us what you think about this case using the comments section in this

ESC 2020 | El Rivaroxaban puede reducir los eventos cardíacos, cerebrales y periféricos

ESC 2020 | Rivaroxaban Might Reduce Cardiac Cerebral and Peripheral Events

Adding rivaroxaban to the standard treatment might reduce events incidence in lower limbs, heart, and brain, in patients with peripheral vascular disease undergoing revascularization.   These new data resulted from the analysis of the VOYAGER PAD subgroups and were presented at the virtual ESC 2020. The COMPASS study had reached similar conclusions using 2.5 mg rivaroxaban

Virtual ACC 2020 | VOYAGER PAD: Rivaroxaban Superior to Aspirin in Preventing Events

In patients with peripheral artery disease undergoing revascularization, the combination of rivaroxaban (Xarelto) and low doses of aspirin are superior to aspirin alone in the prevention of acute low limb ischemic events, amputation, cardiovascular events and strokes. The outcomes of VOYAGER PAD add to the COMPASS outcomes, showing the combination of therapies can benefit risk

Top